NCT04056325View on ClinicalTrials.gov

Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

617

Participants

Timeline

Start Date

November 27, 2019

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Strongyloides Stercoralis Infection
Interventions
DRUG

Moxidectin

Monotherapy, oral administration, single dose, fixed dose

DRUG

Ivermectin

Monotherapy, oral administration, single dose, weight dependent

DRUG

Placebo oral tablet

Monotherapy, oral administration, single dose, matching number of tablets

Trial Locations (1)

Unknown

National Institute of Public Health, Vientiane

All Listed Sponsors
collaborator

National Institute of Public Health, Vientiane, Laos

OTHER

lead

Jennifer Keiser

OTHER

NCT04056325 - Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis | Biotech Hunter | Biotech Hunter